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Abstract 
 
The aim of this study was to develop by means of co-extrusion a multilayer fixed-dose 
combination solid dosage form for oral application characterized by immediate release for 
both layers, the layers containing different drugs with different water-solubility. In this study 
polymers were selected which can be combined in a co-extruded dosage form. Several 
polymers were screened on the basis of their processability via hot-melt extrusion, 
macroscopic properties, ASA decomposition and in vitro drug release. Acetylsalicylic acid 
(ASA) and fenofibrate (FF) were incorporated as hydrophilic and hydrophobic model drugs, 
respectively. Based on the polymer screening experiments Kollidon® PF 12 and Kollidon® VA 
64 were identified as useful ASA carriers (core), while Soluplus®, Kollidon® VA 64 and 
Kollidon® 30 were applicable as FF carriers (coat). The combination of Kollidon® 30 (coat) 
with Kollidon® PF 12 or Kollidon® VA 64 (core) failed in terms of processability via co-
extrusion. All other combinations (containing 20% ASA in the core and 20% FF in the coat) 
were successfully co-extruded (diameter core: 2 mm / thickness coat: 1 mm). All formulations 
showed good adhesion between core and coat. ASA release from the core was complete 
within 15-30 min (Kollidon® PF 12) or 30-60 min (Kollidon® VA 64), while FF release was 
complete within 20-30 min (Kollidon® VA 64) or 60 min (Soluplus®). DSC and XRD revealed 
that both drugs were molecularly dispersed in the carriers. Raman mapping exposed very 
little intermigration of both drugs at the interface. Fixed-dose combinations with good in vitro 
performance were successfully developed by means of co-extrusion, both layers providing 
immediate release. 
KEY WORDS: hot-melt co-extrusion, fixed-dose combination product, drugs with different 
water-solubility, immediate release, solid solutions 
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1. Introduction 
Hot-melt extrusion (HME) technology for pharmaceutical applications has gained 
significant interest in recent years. Even though this technique has been used for decades in 
the plastics and food industry, it is relatively new in the pharmaceutical industry. HME shows 
numerous benefits over traditional methods including the continuity of the production 
process, environmental advantages due to elimination of solvents and the possibility of 
improving drug solubility. The latter has drawn attention because large numbers of new 
chemical entities under development exhibit very poor solubility and bioavailability. 
Formulation of solid solutions via HME can be an efficient approach in the delivery of poorly 
water-soluble drugs. Co-extrusion is defined as the simultaneous extrusion of two or more 
materials through a single die, creating a multi-layered extrudate [1]. The final co-extruded 
product may offer several advantages due to material and composition characteristics 
imparted by the individual polymer layers. These dosage forms allow to modulate drug 
release from the different layers [2, 3] and to simultaneously administer non-compatible 
drugs (formulated in separate layers). Up until now, no co-extruded oral dosage forms are 
available on the market and only a few papers concerning co-extrusion as a manufacturing 
technique for oral drug delivery systems have been published [1-6]. Co-extrusion is gaining 
importance for the production of oral drug products as combination therapy is becoming 
increasingly important as fixed-dose combination (FDC) products offer therapeutic (improved 
patient adherence) and economic (lower manufacturing costs) benefits. Such “polypills” are 
being used in the treatment of e.g. cardiovascular disease, diabetes, hyperlipidemia, HIV, 
tuberculosis and malaria. In this study acetylsalicylic acid (ASA, an anticoagulant) and 
fenofibrate (FF, a lipid regulating drug) were incorporated as hydrophilic and hydrophobic 
model drugs, respectively. While ASA is slightly soluble in water and has relatively high oral 
bioavailability, FF is poorly water-soluble and has a low bioavailability after oral 
administration. Due to their biopharmaceutical and pharmacological properties, immediate 
release of both drugs is required. The aim of this study is to design a core/coat dosage form 
suitable for co-extrusion, whereby the core and coat formulation provide immediate drug 
release (IR) of both drugs (ASA and FF). Several research groups have already investigated 
the feasibility of HME to produce immediate release FF dosage forms. Kollidon® VA 64 [7, 8], 
Eudragit® E PO [8], Soluplus® [9] and blends of PVPVA 64, HPMC and Soluplus® [10] were 
reported.   
2. Materials and methods 
2.1. Materials 
The following polymers were used during the polymer selection procedure: Eudragit® E 
PO (Evonik, Darmstadt, Germany), SentryTM Polyox® WSR N10 (polyethylene oxide, PEO 
100,000 g/mol, Colorcon, Dartford Kent, United Kingdom), Soluplus®, Kollidon® VA 64, PF 12 
and 30 (BASF, Ludwigshafen, Germany). Polyethylene glycol (PEG 4000 g/mol, Fagron, 
Waregem, Belgium) and Pluronic® F-68 (PLUR, Sigma–Aldrich, Steinheim, Germany) were 
used as plasticizers. Fenofibrate (FF, Roig-Farma, Barcelona, Spain) and acetylsalicylic acid 
(ASA, Utag, Amsterdam, The Netherlands) were incorporated as hydrophobic and 
hydrophilic model drug, respectively. All other chemicals were of analytical grade. 
 
2.2. Polymer selection 
For the selection procedure several thermoplastic polymers were hot-melt extruded and 
evaluated for processability, macroscopic properties (visual inspection of surface, die swell 
quantification using marking gauge), salicylic acid content (ASA formulations) and in vitro 
drug release. Polymers/plasticizer were mixed (with mortar and pestle) with FF and ASA 
(concentration range: 20-40%, w/w) and hot-melt extruded using a co-rotating, fully 
intermeshing twin screw extruder (Prism Eurolab 16, ThermoFisher Scientific, Germany) 
having a length-to-diameter ratio of 25/1. The co-rotating screws consisted of three mixing 
sections and a densification zone (Fig. 1). A co-extrusion die (Guill, West Warwick, USA) 
was connected at the end of the extruder. The extrusion temperature varied according to the 
polymer, but all five heating segments of the extruder were set at the same temperature, 
except for the first heating zone which was set at 70 °C to avoid sticking of the powder in the 
feed section. The premixes were fed into the extruder using a loss-in-weight powder feeder 
(Brabender flexwall®, Duisburg, Germany). The screw speed was kept constant at 120 rpm 
and 180 rpm for extrusion of ASA and FF formulations, respectively. ASA formulations were 
extruded through the core orifice of the co-extrusion die, yielding extrudates with a diameter 
of 2 mm. FF formulations were extruded through the coat orifice (1mm coat thickness) 
yielding hollow cylindrical tubes with an outer and inner diameter of 4 and 2 mm, 
respectively. After cooling down to room temperature, the cylindrical extrudates were 
manually cut into mini-matrices of 2 mm length.  
 
2.3. Production of co-extrudates 
Polymer/plasticizer and drug were premixed in a tumbling mixer (Turbula® T2A, W.A. 
Bachofen, Basel, Switzerland) for 20 min. Co-extrusion was performed using two co-rotating, 
fully intermeshing twin screw extruders (Prism Eurolab 16, ThermoFisher Scientific, 
Germany). The co-extrusion die (Guill, West Warwick, USA) was connected to both 
extruders. Both melts were combined in the die to form two concentric layers, a core and a 
coat. All five heating segments of both extruders were set at the same temperature, except 
for the first heating zone which was set at 70 °C to avoid sticking of the powder in the feed 
section. The premixes were fed into the corresponding extruders using loss-in-weight powder 
feeders (Brabender Flexwall®, Duisburg, Germany). The screw speed was kept constant at 
120 rpm (core) and 180 rpm (coat). The co-extrusion die was designed with a core diameter 
of 2 mm and a coat thickness of 1 mm, resulting in a total die diameter of 4 mm. After cooling 
down to room temperature, the cylindrical co-extrudates were manually cut into mini-matrices 
of 2 mm length.  
 
2.4. Determination of free salicylic acid 
The salicylic acid (SA) content in the extrudates was assessed according to the USP 32 
monograph for aspirin tablets.  
 
2.5. In vitro drug release 
Dissolution studies were performed using USP apparatus 1 (baskets). The equipment 
consisted of a VK 7010 dissolution system combined with a VK 8000 automatic sampling 
station (VanKel Industries, NJ, USA). Acetate buffer pH 4.5 containing 0.05 M sodium lauryl 
sulfate was used as dissolution medium [11, 12]. Sink conditions were maintained during the 
experiments. The temperature of the dissolution medium (900 ml) was kept constant at 37 ± 
0.5 °C. The rotational speed of the baskets was set to 100 rpm. Samples (5 ml) were 
withdrawn at 5, 10, 15, 20, 30, 45, 60 (and 90) min.  
ASA and FF concentrations were determined using a validated HPLC method. The HPLC 
equipment (Merck-Hitachi, Darmstadt, Germany) consisted of a gradient solvent pump set at 
a constant flow rate of 1 ml/min, an autosampler, a reversed-phase C-18 column 
(LiChrospher® 100 RP-18 (5 μm)) (250 x 4 mm) and guard column (4 x 4 mm) and a UV 
detector set at 285 nm. The injection volume was 20 µl. An automatic integration system 
(software D-7000 Multi-Manager) was used for peak integration. The mobile phase consisted 
of mixtures of buffer solution pH 2.9 [12] and methanol: initially using a 57:43-ratio (to elute 
ASA and SA, while FF was retained on the column). After 14.5 min the ratio of the mobile 
phase was rapidly changed to 10:90 (to elute the hydrophobic FF from the column), after 
22.0 min the ratio between the aqueous and organic phase was again set at 57:43 and the 
column was equilibrated until 31.0 min prior to the following analysis.  
 
2.6. X-ray diffraction 
X-ray diffraction (XRD) was performed to investigate the crystallinity of the drugs in the 
mini-matrices. X-ray patterns of drug, polymer, physical mixtures and extrudates were 
obtained using a D5000 Cu Kα Diffractor (λ = 0.154 nm) (Siemens, Karlsruhe, Germany). 
The angular range (2θ) varied from 10° to 60° (step width = 0.02°, counting time = 1 s/step). 
 2.7. Differential scanning calorimetry 
Differential scanning calorimetry (DSC) was used to study the solid state properties of the 
extrudates. The thermal behavior of the individual components, physical mixtures and 
extrudates was evaluated using a Q2000 DSC (TA Instruments, Leatherhead, UK). The 
system was equipped with a refrigerated cooling system. Samples (5-10 mg) were accurately 
weighed and hermetically sealed in aluminum pans (TA Instruments, Leatherhead, UK).They 
were cooled to -70 °C, followed by heating to 170 °C at a linear heating rate of 10 °C/min. 
 
2.8. Scanning electron microscopy 
Scanning electron microscopy (SEM) was used to visualize the interface between both 
co-extruded layers. Samples were coated with platinum by means of a sputter coater (Auto 
Fine Coater, JFC-1300, Jeol, Tokyo, Japan). Photomicrographs were taken with a scanning 
electron microscope (Jeol JSM 5600 LV, Jeol, Tokyo, Japan).  
 
2.9. Raman spectroscopy 
The distribution of the different components in the coat and core of the co-extrudates was 
evaluated with Raman microscopic mapping using a Raman Rxn1 Microprobe (Kaiser 
Optical Systems Inc., Ann Arbor, MI, USA), equipped with an air-cooled CCD detector. The 
laser wavelength employed was 785 nm from a Invictus NIR diode laser (Kaiser Optical 
Systems Inc., Ann Arbor, MI, USA). All spectra were recorded with a resolution of 4 cm−1 and 
an exposure time of 7 s, using a laser power of 400 mW. Cross sections of co-extrudates 
were scanned by a 50× short working distance objective lens (spot size 10 µm) in point-by-
point mapping mode using a step size of 10 µm in both the x and y directions. The resulting 
images provide information about the distribution of different components in the co-
extrudates. Data collection and data transfer were automated using the HoloGRAMSTM data 
collection software (version 2.3.5, Kaiser Optical Systems Inc., Ann Arbor, MI, USA). The 
analysis of the spectra was done using HoloMAPTM data analysis software (version 2.3.5, 
Kaiser Optical Systems Inc., Ann Arbor, MI, USA) and Matlab® software (version 7.1, The 
MathWorks Inc., Natick, MA, USA). All spectra were baseline corrected using the Pearsons 
method. To visualize the distribution of the drug within the co-extrudate, a specific peak of 
each drug was shown relatively to a specific peak of the polymer. In order to attribute specific 
Raman peaks in the spectra to the different components in the formulations, Raman spectra 
were collected from the pure components and the separate layers. All spectra were recorded 
with a resolution of 4 cm−1 and an exposure time of 10s. Standard normal variate (SNV) pre-
processing was applied on the collected spectra prior to analysis, to correct for the variation 
in path length/sampling distance between probe and sample.  
 
2.10. Karl Fisher titration 
The moisture content of the polymers and plasticizers at ambient conditions was 
determined by volumetric Karl Fischer titration using a V30 volumetric KF titrator (Mettler 
Toledo, USA). The experiments were performed in triplicate.   
3. Results and discussion 
3.1. Polymer selection  
The aim of this work was to develop a formulation providing immediate release from a co-
extruded dosage form, containing ASA as hydrophilic model drug and FF as hydrophobic 
model drug. Several thermoplastic polymers were therefore hot-melt extruded in combination 
with ASA and FF, and evaluated for processability (torque and die pressure), macroscopic 
properties (surface, transparency, consistency and die swell), ASA decomposition (via SA 
content determination) and in vitro drug release. Polymers that failed one criterion, i.e. were 
not processable below 140 °C with a torque value of <80% motor load and a die pressure of 
<100 bar, exhibited unfavorable macroscopic properties (irregular surface, sticky, irregular 
dimensions), contained >3% SA or did not release 80% of the drug in approximately 45 min, 
were rejected.  
3.1.1. ASA 
Five polymers (PEO, Eudragit® E PO, Soluplus®, Kollidon® VA 64 and Kollidon® PF 
12) were tested during ASA-polymer screening. Table 1 presents the composition, extrusion 
temperature, SA content and in vitro drug release of the screened formulations. All polymers 
were processable via hot melt extrusion at the specified temperatures. All PEO/ASA 
extrudates (extruded at 75 °C) were smooth, slightly yellow and transparent. However, they 
became opaque after cooling down to room temperature as PEO recrystallized. Process 
monitoring revealed that the addition of PEG 4000 as a plasticizer resulted in lower die 
pressures and torque values. Unplasticized Eudragit® E PO/ASA mixtures had a minimum 
extrusion temperature of 140 °C. The incorporation of PEG 4000 improved processing by 
lowering the extruder torque and die pressure. The addition of 25% PEG allowed extrusion at 
120 °C. Eudragit® E PO/ASA extrudates were slightly yellow but transparent. They exhibited 
unfavorable macroscopic properties as they were very flexible and sticky. Extrusion of pure 
Soluplus® requires a temperature of 120-200 °C [13]. Soluplus®/ASA mixtures were 
processable at a minimum temperature of 110 °C and good quality extrudates (smooth, 
clear, rigid, not sticky) were obtained, but with a slight pink discoloration. This discoloration 
was probably due to the formation of complexes between salicylic acid (ASA degradation) 
and free iron ions originating from the extrusion screws or barrel due to shear [14]. The 
addition of 1% sodium EDTA eliminated the pink discoloration, which supported our 
hypothesis. For the processing of Kollidon® VA 64/ASA extrudates a temperature of at least 
130 °C was required. The extrudates were clear and smooth but the same pink discoloration 
as seen with Soluplus® appeared. Again, the problem was solved by adding 1% sodium 
EDTA. Kollidon® PF 12 was processable at a temperature of 110 °C. The quality of all 
Kollidon® PF 12/ASA extrudates was good (clear, rigid) and no discoloration was noticed. It 
was found in literature that Kollidon® forms complexes in solution with salicylic acid, which 
could be a possible explanation for the absence of the pink discoloration [15]. No significant 
die swell was observed for any of the tested polymers. 
ASA undergoes thermal decomposition as is starts to decompose upon melting (140 
°C) [16], while in the presence of water hydrolysis of ASA results in the formation of SA and 
acetic acid. Therefore the polymers that yielded good quality extrudates (PEO, Soluplus®, 
Kollidon® VA 64 and Kollidon® PF 12), were further tested for salicylic acid content (Table 1). 
The USP SA limits [11] for ASA tablets (≤0,3%) or coated ASA tablets (≤3%) were used as 
reference values, although solid dispersions do not comply with either dosage forms. For all 
PEO/ASA formulations a large amount of SA was formed during extrusion. No correlation 
between moisture content and SA concentration could be demonstrated. It was found that 
the SA content decreased (26.6, 17.8, 12.0% SA) with increasing PEG concentration (0, 25, 
50% PEG) and decreasing torque (60, 30, 15% motor load) and die pressure (55, 30, 13 
bar). Breitenbach [17] stated that high shear forces can lead to a local temperature increase 
within the extrusion barrel. In addition, Breitenbach identified the residence time and die 
pressure as factors with a significant impact on the impurity profile. These findings support 
our hypothesis that the extruder torque and die pressure may play a role in ASA degradation 
during extrusion. The degree of decomposition in extrudates with Soluplus® as carrier was 
lower in comparison with PEO formulations, as it was possible to approach the USP limit of 
≤3%. Nevertheless, the only two polymers that complied with the SA limit were Kollidon® VA 
64 and Kollidon® PF 12, containing 2.4 and 1.5% SA respectively. Kollidon® VA 64 and 
Kollidon® PF 12, the polymers that complied with the criteria of processability and ASA 
stability, were tested for in vitro drug release. The ASA release from Kollidon® VA 64 was 
complete in 20 min, whereas the release from Kollidon® PF 12 was already complete in 10 
min.  
 
3.1.2. FF 
Five polymers (PEO, Soluplus®, Eudragit® E PO, Kollidon® VA 64 and Kollidon® 30) 
were tested as FF carriers. Due to the plasticizing properties of FF, Kollidon® PF 12 (used 
during ASA polymer screening) was replaced by Kollidon® 30 exhibiting a higher Tg (149 °C 
instead of 90 °C). Table 2 presents the composition, extrusion temperature and in vitro drug 
release of the screened formulations. All polymers were processable via hot-melt extrusion at 
the specified temperatures. Unplasticized PEO/FF mixtures had a minimum extrusion 
temperature of 100 °C as the die pressure exceeded 100 bar at lower process temperatures. 
PEO/PEG/FF mixtures could be extruded at 75 °C, although torque and die pressure 
increased at lower PEG concentration. Soluplus® (loaded with 20-30% FF) was processable 
at a temperature of 100 °C. Apparently, an increase in FF concentration (20-30% FF) 
improved the ease of processing by lowering the Tg (from 30.0 to 15.0 °C). FF melted during 
processing since the process temperature (100 °C) exceeded its melting point (80 °C). All 
Soluplus® extrudates exhibited a smooth surface. All extrudates up to 30% FF were 
transparent. Eudragit® E PO (loaded with 20% FF) was processable at a temperature of 120 
°C without the addition of a plasticizer. Increasing FF concentrations improved the ease of 
processing by lowering the extruder torque and die pressure. Consequently the extrusion 
temperature of mixtures containing 30% and 40% FF was lowered to 110°C and 100°C, 
respectively. All Eudragit® E PO/FF extrudates were transparent when they emerged from 
the die. However, the extrudates had unfavorable properties as they were sticky and 
collapsed after cooling down to room temperature. Kollidon® VA 64/FF mixtures (20-40% FF) 
were processable between 100 and 130 °C. As observed for Soluplus® and Eudragit® E PO, 
the ease of processing enhanced at increasing FF loads. Clear extrudates with good quality 
(no die swell, thin, smooth, clear and rigid) were obtained. Kollidon® 30 loaded with 30% FF 
was extrudable at 150 °C. Increasing the drug load to 40% slightly enhanced the 
processability. However, the minimal extrusion temperature remained 150 °C as the die 
pressure increased sharply at lower temperature. All extrudates were clear during extrusion 
and remained clear after cooling down to room temperature. Good quality extrudates (no die 
swell, rigid, clear and a smooth surface) were obtained.  
The polymers that yielded good quality extrudates were further tested for in vitro drug 
release (data not shown). The time required for complete FF release from the different 
formulations is shown in Table 2. FF release from PEO extrudates was incomplete after 1 h. 
Although the addition of PEG to PEO resulted in a considerable increase in release rate, the 
drug release rate remained too low. FF release from Soluplus® extrudates was nearly 
complete after 1 h. A higher drug load did not influence the release rate significantly. 
Although Soluplus® offers the particular advantage that precipitation and crystallization of 
drugs during dissolution is prevented as a result of its micellar character [13], the FF release 
rate was lower than expected. Hughey et al. described that Soluplus® tended to form a strong 
gel (in vitro) and that dissolution occured through erosion of the matrix [18]. Recently, 
Soluplus® was also found to tailor (delay) the release of another hydrophilic drug 
(acetaminophen) [19]. Complete FF release from all formulations formulated with Kollidon® 
VA 64 and Kollidon® 30 was achieved within 20 min.  
 
3.2. Co-extrusion 
A successful co-extrusion process requires that both melts flow through the co-extrusion 
die under the same temperature conditions. Based on the polymer screening data, the 
following formulations were identified as potentially useful for co-extrusion: Soluplus®, 
Kollidon® VA 64 and Kollidon® 30 as FF carriers (coat) in combination with Kollidon® VA 64 or 
Kollidon® PF 12 as ASA carriers (core). The ASA:FF ratio in all formulations was 35:65, 
which complied with the ratio of 80 mg ASA and 145 mg FF (usual daily dose). As the coat 
had a total volume of ±19 mm3 versus ±6 mm3 for the core, FF was formulated in the core. 
The content of ASA and FF in the co-extrudates was ensured by setting correct combinations 
of feed rate and drug load in both processes. 
The combination of Kollidon® 30 as carrier for FF with Kollidon® VA 64 or Kollidon® PF 12 
as carriers for ASA failed in terms of processability. Using the minimum possible die 
temperature for Kollidon® 30 (125 °C) the core formulations with Kollidon® VA 64 and 
Kollidon® PF 12 were too liquid as they left the die resulting in collapse during cooling down 
to room temperature. The co-extrusion trials showed that Kollidon® VA 64 and Kollidon® PF 
12 as carrier for ASA were compatible with Kollidon® VA 64 and Soluplus® as carrier for FF in 
terms of extrusion temperature. The composition as well as the extrusion conditions used for 
each formulation are shown in Table 3. The core and coat of co-extrudate F2 were 
processable at the same temperature (barrel: 130 °C, die: 105 °C). As the core and coat of 
F1, F3 and F4 had different extrusion temperatures (cfr. polymer selection), temperature 
adjustments were required to enable the co-extrusion of these formulations. Nevertheless, all 
four formulations had good macroscopic properties as they were transparent and exhibited 
no die swell. Furthermore, both layers adhered firmly as no delamination was observed (Fig. 
2). In addition, the thickness of the coat and core was uniform, as confirmed with a marking 
gauge. After extrusion, the core and coat of the co-extrudates were physico-chemically 
characterized. The thermogram of all coat formulations revealed that there was no crystalline 
FF present in formulation F1, F2 (Fig. 3A), F3 and F4 (Fig. 3B). For all formulations, a single 
glass transition temperature (44.80 °C (F1 and F2), 32.73 °C (F3 and F4)) was detected, lying 
in between the individual glass transitions of FF (-21 °C) and Kollidon® VA 64 (101 °C) or 
Soluplus® (70 °C). This indicated the presence of a molecular dispersion. The DSC 
thermogram of ASA showed a melting peak at 144.18 °C (Fig. 4). This peak was absent in 
the thermogram of all core formulations, indicating the loss of crystallinity of ASA in the core 
of the co-extrudates. Since the melting point of ASA was never reached during the extrusion 
process, this indicated that ASA had dissolved in the matrices. A single glass transition 
temperature (30.15 °C (F1 and F3), 39.71 °C (F2 and F4)) was detected, lying in between the 
individual glass transitions of FF (-21 °C) and Kollidon® PF 12 (90 °C) or Kollidon® VA 64 
(101 °C). These results were confirmed with XRD (data not shown). The SA content in all 
core formulations 1.7 ± 0.12 for F1 and F3 and 2.3 ± 0.29 for F2 and F4 was in agreement with 
those found during the polymer screening tests (Table 1). 
To evaluate the drug distribution in core and coat, Raman microscopic mapping was 
performed. The peak intensity of the Raman band of ASA in the 745-760 cm−1 region was 
monitored to map the ASA distribution in the core and to check if migration of ASA to the 
coat of the co-extrudates had occurred during co-extrusion. Likewise, the FF distribution in 
coat and core was mapped by monitoring the peak intensity of the Raman band of FF in the 
760-778 cm−1 region. Fig. 5 shows the distribution of ASA throughout co-extruded 
formulation F1. A red color corresponds to a high peak intensity, indicating a high ASA 
concentration, while a blue color corresponds to a low ASA concentration. The ASA band in 
the 745-760 cm−1 region showed an intense peak in the core. A very low peak intensity was 
found in the coat at the interface with the core (light blue), indicating very little migration of 
ASA to the coat. Comparing the Raman spectra of the light blue area with those of the 
individual drugs (Fig. 6), it was demonstrated that the light blue area contained both drugs. 
The FF band in the 760-778 cm−1 region showed an intense peak in the coat and not in the 
core. However, a low FF peak intensity was found in the core at the interface with the coat 
(yellow), indicating very little migration of FF in the core. Comparing the Raman spectra of 
the yellow area with those of the individual drugs (Fig. 6), it was demonstrated that the yellow 
area contains both drugs. The mapping results of all other formulations were similar (data not 
shown). Core and coat were clearly distinguished from one another, with a small region (10 
µm) of intermigration in between.  
  
The FF release from F1, F2, F3 and F4 was complete in 20, 30, 60 and 60 min, 
respectively (Fig. 7) and was not considered significantly different from the dissolution of the 
individual coat formulations during screening. Furthermore, the Kollidon® VA 64-based coat 
of F1 and F2 did not influence ASA release from the cores. ASA release from the Kollidon® 
VA 64 core (F4) was clearly hindered by the Soluplus® coat. In comparison with the ASA 
release observed during the polymer screening (individual core), the ASA release rate from 
co-extrudate F4 was significantly decreased (complete release after ± 60 min instead of 20 
min). It was hypothesized that the Soluplus®-based coat partially covered the core surface 
during dissolution, thereby hindering ASA release. 
 
4. Conclusions 
This study identified co-extrusion as a promising technique to produce a multilayer 
FDC solid dosage form for oral application characterized by immediate release from both 
layers. Extrusion of ASA was challenging as in some carriers degradation to SA was 
observed, despite of the absence of water during thermal processing. However, core/coat 
dosage forms were successfully developed using four different polymer combinations: 
Kollidon® PF 12/Kollidon® VA 64, Kollidon® PF 12/Soluplus®, Kollidon® VA 64/Kollidon® 
VA 64 and Kollidon® VA 64/Soluplus®. All combinations showed good processability via 
co-extrusion, and the adhesion between core and coat was good. The solid state 
characterization revealed that both ASA and FF were molecularly dispersed in the co-
extrudates. Raman mapping exposed very little intermigration of both drugs at the 
interface. Further investigation will be required to evaluate the stability of the co-extruded 
solid solutions.  
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Tables 
Table 1: Overview of polymer screening results for ASA. 
Carrier ASA (%) Tdie - Textrusion* SA content (%)  Complete release (min) 
PEO (0-50 % PEG)  20 75 - 75 26.6 (± 0.17) -12.0 (± 0.23)  not tested*** 
Eudragit® E PO (0-25% PEG) 20 120 - 140-120   not tested** not tested** 
Soluplus®  20  95 - 110  4.7 (± 0.21) not tested*** 
Kollidon® VA 64  20 105 - 130  2.4 (± 0.11) 20 
Kollidon® PF 12  20 95 - 110 1.5 (± 0.16) 10 
*: lowest extrusion temperature usable resulting in a torque value of <80% motor load and a pressure of <100 bar. 
**: too sticky and highly flexible  
***: SA content >3% 
 
  
Table 2: Overview of polymer screening results for FF. 
Carrier FF (%) Tdie-Textrusion (°C)* Complete release (min) 
PEO (0-50 % PEG) 20 75 - 100-75 >60  
Soluplus®  20-30 100 - 100 ±60 
Eudragit® E PO 20-40 100 - 120-100 not tested** 
Kollidon® VA 64 20 105 - 130 20 
 30-40 100 - 100 20 
Kollidon® 30 30-40 125 - 150 20 
*: lowest extrusion temperature usable resulting in a torque value of <80% motor load and a pressure of <100 bar. 
**: too sticky and highly flexible 
 
  
Table 3: Composition and extrusion parameters of co-extruded formulations. 
 Carrier Drug concentration (%) Extrusion temperature (°C) Feed rate (g/h) 
 Core Coat Core (ASA) Coat (FF) Core Coat Die Core Coat 
F1 Kollidon® PF 12 Kollidon® VA 64 20 20 120 130 95 300 545 
F2 Kollidon® VA 64 Kollidon® VA 64 20 20 130 130 105 300 545 
F3 Kollidon® PF 12 Soluplus® 20 20 120 100 95 300 545 
F4 Kollidon® VA 64 Soluplus® 20 20 130 105 105 300 545 
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